Analystreport

Turning Point Therapeutics (NASDAQ: TPTX) had its "buy" rating re-affirmed by analysts at Roth Capital. They now have a $77.00 price target on the stock, up previously from $75.00.

Turning Point Therapeutics, Inc. - Common stock  (TPTX) 
Last turning point therapeutics, inc. - common stock earnings: 3/16 09:00 am Check Earnings Report